KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Net Income (2016 - 2025)

Historic Net Income for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$128.6 million.

  • Ionis Pharmaceuticals' Net Income rose 845.24% to -$128.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$257.0 million, marking a year-over-year increase of 2852.59%. This contributed to the annual value of -$454.5 million for FY2024, which is 2384.37% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Net Income stood at -$128.6 million, which was up 845.24% from $123.6 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Net Income high stood at $223.7 million for Q4 2021, and its period low was -$147.4 million during Q3 2023.
  • Moreover, its 5-year median value for Net Income was -$85.3 million (2023), whereas its average is -$67.0 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Net Income tumbled by 94959.52% in 2024 and then soared by 28644.99% in 2025.
  • Ionis Pharmaceuticals' Net Income (Quarter) stood at $223.7 million in 2021, then tumbled by 123.66% to -$52.9 million in 2022, then surged by 81.1% to -$10.0 million in 2023, then crashed by 949.6% to -$105.0 million in 2024, then decreased by 22.47% to -$128.6 million in 2025.
  • Its last three reported values are -$128.6 million in Q3 2025, $123.6 million for Q2 2025, and -$146.9 million during Q1 2025.